NuGenerex Immuno-Oncology Announces the Cancellation of Shareholder Conference Call Originally Scheduled for Today, Thursday, August 27, 2020

MIRAMAR, Fla., Aug. 27, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO) today announced that it has cancelled the investor conference call originally scheduled to be held, Thursday, August 27, 2020 at 9:30 am.

The conference call has been cancelled because the updates on the Ii-Key-SARS-CoV-2 vaccine, the potential deals with Malaysia and China, the planned meeting with the Canadian National Research Council, also the planned listing of NGIO on a national exchange were all discussed on today’s conference call with Generex shareholders.

Mr. Moscato said, “We are sorry to cancel this call at the last minute, but all of the topics we planned to cover on the call were covered in yesterday’s shareholders call. The audio transcript is on our website for review and the written transcript will be available on the company web site at in the coming days. Please listen to the audio transcript or read the written transcript to get the updates on NGIO and the Ii-Key-SARS-CoV-2 vaccine program. If you have further questions, you can email and we will get back to you.”

About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products. 

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato

Todd Falls
1-800-391-6755 Extension 222 

Primary Logo

Back to news